Sandbox:skorjian2

Title of Guidelines	Year	Class III Recommendation	Level of Evidence	Effect	Key Word
ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery	2014	Routine use of pulmonary artery catheterization in patients, even those with elevated risk, is not recommended.	A	No Benefit	Cardiac evaluation for non cardiac surgery
ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery	2009	Routine use of a PAC perioperatively, especially in patients at low risk of developing hemodynamic disturbances, is not recommended.	A	N/A	Perioperative Beta Blockade
ACCF/AHA Guideline for the Management of Heart Failure	2013	Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use.	A	No Benefit	Heart failure
ACCF/AHA Guideline for the Management of Heart Failure	2013	Calcium channel–blocking drugs are not recommended as routine treatment for patients with HFrEF	A	No Benefit	Heart failure
ACCF/AHA Guideline for the Management of Heart Failure	2013	Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use.	A	No Benefit	Heart failure
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease	2012	Estrogen therapy is not recommended in postmenopausal women with SIHD with the intent of reducing cardiovascular risk or improving clinical outcomes.	A	No Benefit	Ischemic heart disease
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease	2012	Treatment of elevated homocysteine with folate or vitamins B6 and B12 is not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD.	A	No Benefit	Ischemic heart disease
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease	2012	Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD.	A	No Benefit	Ischemic heart disease
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention	2011	Administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced acute kidney injury.	A	No Benefit	PCI
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention	2011	Cutting balloon angioplasty should not be performed routinely during PCI.	A	No Benefit	PCI
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention	2011	Laser angioplasty should not be used routinely during PCI.	A	No Benefit	PCI
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention	2011	Rotational atherectomy should not be performed routinely for de novo lesions or in-stent restenosis.	A	No Benefit	PCI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	Antioxidant vitamin supplements (eg, vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS.	A	No Benefit	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	Folic acid, with or without vitamins B6 and B12, should not be used for secondary prevention in patients with NSTE-ACS.	A	No Benefit	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks.	A	Harm	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	In patients with NSTE-ACS (ie, without ST-elevation, true posterior Ml, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used.	A	Harm	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS.	A	No Benefit	NSTEMI
AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease	2014	Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D).	A	No Benefit	Valvular heart disease
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science	2010	Management of Arrhythmias,Ventricular Rhythm Disturbances Prophylactic administration of lidocaine is not recommended	A	N/A	Cardiopulmonary Resuscitation
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science	2010	Management of Arrhythmias,Ventricular Rhythm Disturbances Pprophylactic antiarrhythmics are not recommended for patients with suspected ACS or myocardial infarction in the prehospital or ED	A	N/A	Cardiopulmonary Resuscitation
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science	2010	Cardiac Arrest Associated With Pulmonary Embolism In patients with cardiac arrest and without known PE, routine fibrinolytic treatment given during CPR shows no benefit185,186 and is not recommended	A	N/A	Cardiopulmonary Resuscitation
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science	2010	Other Vasopressors,Magnesium Sulfate Routine administration of magnesium sulfate in cardiac arrest is not recommended unless torsades de pointes is present.	A	N/A	Cardiopulmonary Resuscitation
ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease	2008	Pregnancy in patients with ASD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged.	A	N/A	Congenital heart disease
ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease	2008	Pregnancy in patients with VSD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged.	A	N/A	Congenital heart disease
ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery	2014	Routine use of pulmonary artery catheterization in patients, even those with elevated risk, is not recommended.	A	No Benefit	Cardiac risk evaluation for non-cardiac surgery
ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults	2013	CK should not be routinely measured in individuals receiving statin therapy.	A	No benefit	Dyslipidemia
ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults	2013	It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.	A	Harm	Dyslipidemia
ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)	2005	Chelation (e.g., ethylenediaminetetraacetic acid) is not indicated for treatment of intermittent claudication and may have harmful adverse effects.	A	N/A	Peripheral arterial disease
ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)	2005	Intervention is not recommended for asymptomatic infrarenal or juxtarenal AAAs if they measure less than 5.0 cm in diameter in men or less than 4.5 cm in diameter in women.	A	N/A	Peripheral arterial disease
ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)	2005	Oral vasodilator prostaglandins such as beraprost and iloprost are not effective medications to improve walking distance in patients with intermittent claudication.	A	N/A	Peripheral arterial disease
ACC/AHA/ESC Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death	2006	Class IC antiarrhythmic drugs in patients with a past history of MI should not be used.	A	No Benefit	Ventricular arrhythmias
ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities	2008	Permanent pacing is not indicated for torsade de pointes VT due to reversible causes.	A	N/A	Device-based therapy
ACCF/AHA Guideline for the Management of Heart Failure	2013	Calcium channel–blocking drugs are not recommended as routine treatment for patients with HFrEF.	A	No Benefit	Heart Failure
ACCF/AHA Guideline for the Management of Heart Failure	2013	Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use	A	No Benefit	Heart Failure
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease	2012	Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD	A	No Benefit	Stable ischemic heart disease
ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities		Permanent pacing is not indicated for torsade de pointes VT due to reversible causes.	A	N/A	Cardiac Rhythm Abnormalities
AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery	2015	Among patients with LV dysfunction (EF <35%), ICD therapy is not recommended for the prevention of sudden cardiac death after CABG until 3 months of postoperative goal-directed medical therapy has been provided and persistent LV dysfunction has been confirmed	A	N/A	CABG
AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery	2015	Warfarin should not be routinely prescribed after CABG for graft patency unless patients have other indications for long-term antithrombotic therapy (such as AF, venous thromboembolism, or a mechanical prosthetic valve)	A	N/A	CABG
AHA Scientific Statement: Diagnosis and Treatment of Fetal Cardiac Disease	2014	Fetal medical therapy is of no benefit for fetuses with sinus bradycardia, irregular rhythms caused by extrasystolic beats.	A	N/A	Fetal cardiac disease
AHA Scientific Statement: Diagnosis and Treatment of Fetal Cardiac Disease	2014	Referral for fetal cardiac evaluation is not indicated for maternal medications including SSRIs (other than paroxetine).	A	N/A	Fetal cardiac disease
AHA Scientific Statement: Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension	2011	Systemic fibrinolysis should not be given routinely to patients with IFDVT.	A	N/A	Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
AHA Scientific Statement: The Postthrombotic Syndrome Evidence-Based Prevention, Diagnosis, and Treatment Strategies	2014	Recommendations for Thrombolysis and Endovascular Approaches to Acute DVT for the Prevention of PTS Systemic thrombolysis is not recommended for the treatment of DVT	A	N/A	Postthrombotic Syndrome
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	Antioxidant vitamin supplements (eg, vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS.	A	No Benefit	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	Folic acid, with or without vitamins B6 and B12, should not be used for secondary prevention in patients with NSTE-ACS.	A	No Benefit	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks.	A	Harm	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	In patients with NSTE-ACS (ie, without ST-elevation, true posterior MI, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used.	A	Harm	NSTEMI
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes	2014	With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS.	A	No Benefit	NSTEMI
AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease	2014	Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D).	A	No Benefit	Valvular heart disease
AHA Scientific Statement: Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates	2012	Initiating beta-blocker therapy in beta-blocker–naïve patients the night before and/or the morning of noncardiac surgery is not recommended	A	N/A	Kidney and Liver Transplantation Candidates
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: Update	2008	Delayed evacuation by craniotomy appears to offer little if any benefit with a fairly high degree of certainty. In those patients presenting in coma with deep hemorrhages, removal of ICH by craniotomy may actually worsen outcome and is not recommended.	A	N/A	Spontaneous Intracerebral Hemorrhage
Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease	2011	Except in extraordinary circumstances, carotid revascularization by either CEA or CAS is not recommended when atherosclerosis narrows the lumen by less than 50%.	A	No Benefit	Extracranial Carotid and Vertebral Artery Disease
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	At present, no pharmacological agents with putative neuroprotective actions have demonstrated efficacy in improving outcomes after ischemic stroke, and therefore, other neuroprotective agents are not recommended	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	Because of lack of evidence of efficacy and the potential to increase the risk of infectious complications, corticosteroids (in conventional or large doses) are not recommended for treatment of cerebral edema and increased ICP complicating ischemic stroke	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	Frank hypodensity on NECT may increase the risk of hemorrhage with fibrinolysis and should be considered in treatment decisions. If frank hypodensity involves more than one third of the MCA territory, intravenous rtPA treatment should be withheld	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	Hemodilution by volume expansion is not recommended for treatment of patients with acute ischemic stroke	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	The administration of vasodilatory agents, such as pentoxifylline, is not recommended for treatment of patients with acute ischemic stroke	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	The intravenous administration of streptokinase for treatment of stroke is not recommended	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	Urgent anticoagulation for the management of noncerebrovascular conditions is not recommended for patients with moderate-to-severe strokes because of an increased risk of serious intracranial hemorrhagic complications	A	N/A	Acute ishemic stroke
AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke	2013	Urgent anticoagulation, with the goal of preventing early recurrent stroke, halting neurological worsening, or improving outcomes after acute ischemic stroke, is not recommended for treatment of patients with acute ischemic stroke	A	N/A	Acute ishemic stroke
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group	2008	With a few exceptions, the routine evacuation of supratentorial ICH by standard craniotomy within 96 hours of ictus is generally not recommended.	A	N/A	Spontaneous Intracerebral Hemorrhage
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack	2014	For patients with a cryptogenic ischemic stroke or TIA and a PFO without evidence for DVT, available data do not support a benefit for PFO closure	A	N/A	Prevention of stroke
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack	2014	For patients with a recent (within 6 months) TIA or ischemic stroke ipsilateral to a stenosis or occlusion of the middle cerebral or carotid artery, EC/IC bypass surgery is not recommended	A	N/A	Prevention of stroke
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack	2014	Routine supplementation with a single vitamin or combination of vitamins is not recommended	A	N/A	Prevention of stroke
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack	2014	The combination of aspirin and clopidogrel, when initiated days to years after a minor stroke or TIA and continued for 2 to 3 years, increases the risk of hemorrhage relative to either agent alone and is not recommended for routine long-term secondary prevention after ischemic stroke or TIA	A	N/A	Prevention of stroke
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack	2014	When the degree of stenosis is <50%, CEA and CAS are not recommended	A	N/A	Prevention of stroke
AHA/ASA Guidelines for the Primary Prevention of Stroke	2011	Aspirin is not useful for preventing a first stroke in persons at low risk	A	N/A	Primary prevention of stroke
AHA/ASA Guidelines for the Primary Prevention of Stroke	2011	Hormone therapy (CEE with or without MPA) should not be used for primary prevention of stroke in postmenopausal women	A	N/A	Primary prevention of stroke
AHA/ASA Guidelines for the Primary Prevention of Stroke	2011	Screening for cardiac conditions such as PFO in the absence of neurological conditions or a specific cardiac cause is not recommended	A	N/A	Primary prevention of stroke
AHA/ASA Guidelines for the Primary Prevention of Stroke	2011	SERMs, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke	A	N/A	Primary prevention of stroke
AHA/ASA Guidelines for the Primary Prevention of Stroke	2011	Treatment with antibiotics for chronic infections as a means to prevent stroke is not recommended	A	N/A	Primary prevention of stroke
ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery	2009	Routine use of a PAC perioperatively, especially in patients at low risk of developing hemodynamic disturbances, is not recommended.	A	N/A	Perioperative Beta Blockade
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease	2012	Estrogen therapy is not recommended in postmenopausal women with SIHD with the intent of reducing cardiovascular risk or improving clinical outcomes.	A	No Benefit	Stable ischemic heart disease
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease	2012	Treatment of elevated homocysteine with folate or vitamins B6 and B12 is not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD	A	No Benefit	Stable ischemic heart disease